Michael Beyer, MD
Ophthalmology · Palos Heights, ILNPI 1144750399
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,204 of the $3,181 with a category attached, or 69.3%. 13 manufacturers reported payments, led by Bausch & Lomb, A Division Of Bausch Health US, LLC at 53.4% of the total. Reporting peaked in 2019 at $1,969 and has fallen 90.4% since, to $189 in 2025.
Across 49 payments — averaging $64.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
- Alcon$892
- Sight Sciences, Inc.$208
- Bausch & Lomb Americas Inc.$111
- Johnson & Johnson Surgical Vision, Inc.$62
- Rxsight Inc$37
- plus $172 from 7 others
What the payments were for
- Travel & lodging$97731%
- Food & beverage$2,20469%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 18 | $1,699 |
| Alcon | 14 | $892 |
| Sight Sciences, Inc. | 4 | $208 |
| Bausch & Lomb Americas Inc. | 1 | $111 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $62 |
| Rxsight Inc | 1 | $37 |
| AbbVie | 2 | $30 |
| Novartis | 1 | $28 |
| Rayner Intraocular Lenses Limited | 1 | $27 |
| Thea Pharma Inc. | 1 | $25 |
| NEW World Medical,inc. | 1 | $24 |
| Oyster Point Pharma, Inc. | 1 | $19 |
| Tarsus Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELLARIS PC$1,042
- CRYSTALENS$1,042
- AKREOS AO$1,042
- ENVISTA$1,042
- TRULIGN TORIC$1,042
- AcrySof$253
- enVista MX60 IOL$222
- OMNI(R) SURGICAL SYSTEM (US)$144
- AcrySof IQ VIVITY IOL$132
- LOTEMAX SM$125
- VYZULTA$116
- enVista Aspire IOL$111
- Centurion$103
How this compares
$3,181 in reported general payments places this provider in the 70th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 13 | $13,035 |
| RestasisCyclosporine | 14 | $11,876 |
| Prednisolone Acetate | 270 | $8,154 |
| Brimonidine Tartrate | 109 | $6,198 |
| Latanoprost | 657 | $5,183 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 154 | $2,921 |
| Ofloxacin | 216 | $2,023 |
| Timolol Maleate | 96 | $865 |
| Ketorolac Tromethamine | 37 | $519 |
| Dorzolamide Hcl | 16 | $286 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 20 | $153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra | $111 | $13,03513 claims |
| AbbVieRestasis | $30 | $11,87614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Palos Heights
- Seenu HariprasadChicago$2.3M
- Lisa NijmSpringfield$1.7M
- Kathleen MornoNorth Riverside$1.2M
- Veeral ShethOak Forest$716K
- James KatzDes Plaines$642K
- Mitchell JacksonLake Villa$584K
- David LubeckHomewood$575K
- Parag MajmudarHighland Park$451K
- Daniel OwensLombard$343K
- Yannek LeidermanChicago$312K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.